Konstantinos Xynos
Förmögenhet: 3 M $ per 2026-07-31
Förmögenhet: 3 M $ per 2026-07-31
Konstantinos Xynos is Chief Medical Officer at Replimune Group, Inc. since 2022.
Formerly, Dr. Xynos was Vice President & Head-Global Medical Affairs at Deciphera Pharmaceuticals, Inc. from 2019 to 2021.
Education includes an undergraduate degree from the University of Illinois (1991), a doctorate from Aristotle University of Thessaloniki (1997), a doctorate from National & Kapodistrian University of Athens (2012), and an MBA from the University of Strathclyde (2013).
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. 0,29 % | 2026-08-10 | 224 215 ( 0,29 % ) | 3 M $ | 2026-07-31 |
| Företag | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2022-12-01 |
| Företag | Position | Slut |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2021-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristotle University of Thessaloniki
Aristotle University of Thessaloniki Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National & Kapodistrian University of Athens
National & Kapodistrian University of Athens Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån